908 Devices is on a strong financial and strategic roll, reporting a 23% revenue surge to $16.1 million in Q2 2026, driven by booming demand from state and local governments upgrading detection tech for fentanyl and chemical threats. Cost-cutting efforts are paying off, slashing adjusted EBITDA loss by 50% to under $2 million. The recent acquisition of NIRLAB adds AI-powered drug analysis to their arsenal, completing their law enforcement suite. With over 750 FTIR devices shipped in two years and rising adoption of VipIR and MX908 models, they’re scaling proven tech while expanding into new markets. A $6M Asia-Pacific order for ProtectIR and growing traction for XplorIR—targeting gases and vapors amid rising chemical incidents—signal momentum. The company is executing its strategy with confidence, building a more resilient and globally positioned business for the rest of 2026 and beyond.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
